The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies

@article{Mller1998TheFC,
  title={The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies},
  author={K. M. M{\"u}ller and K. Arndt and W. Strittmatter and A. Pl{\"u}ckthun},
  journal={FEBS Letters},
  year={1998},
  volume={422}
}
  • K. M. Müller, K. Arndt, +1 author A. Plückthun
  • Published 1998
  • Chemistry, Medicine
  • FEBS Letters
    • Bispecific miniantibodies were constructed by genetically fusing the CH1 domain of an IgG1 to the C‐terminus of a single‐chain Fv fragment (scFv‐425), specific for the EGF receptor, and fusing the CL domain of a kappa light chain to the C‐terminus of a scFv specific for CD2 (scFv‐M1). An efficient dicistronic gene arrangement for functional expression in Escherichia coli was constructed. Immunoblots demonstrated correct domain assembly and the formation of the natural CH1‐CL disulfide bridge… CONTINUE READING
    View on Wiley
    febs.onlinelibrary.wiley.com
    76 Citations
    Highly Influential Citations
    3
    Background Citations
    23
    Methods Citations
    12
    76 Citations
    Citation Type

    Citation Type

    A dimeric bispecific miniantibody combines two specificities with avidity
    • 71
    Fab Chains As an Efficient Heterodimerization Scaffold for the Production of Recombinant Bispecific and Trispecific Antibody Derivatives1
    • 58
    • Highly Influenced
    • PDF
    Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1
    • 15
    Development of a bispecific antibody tetramerized through hetero‐associating peptides
    • 9
    Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
    • 56
    Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments.
    • 34
    A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain.
    • 20
    Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    • 170
    Helix-stabilized Fv (hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain.
    • 59
    • PDF
    An efficient route to the production of an IgG-like bispecific antibody.
    • 35
    • PDF

    References

    SHOWING 1-10 OF 42 REFERENCES
    Design and production of novel tetravalent bispecific antibodies
    • 188
    Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.
    • 322
    • PDF
    A comparison of strategies to stabilize immunoglobulin Fv-fragments.
    • 455
    • PDF
    Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity.
    • 24
    Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli.
    • 300
    • PDF
    Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting.
    • 152
    • PDF
    "Diabodies": small bivalent and bispecific antibody fragments.
    • 822
    • PDF
    New protein engineering approaches to multivalent and bispecific antibody fragments.
    • A. Plückthun, P. Pack
    • Chemistry, Medicine
    • Immunotechnology : an international journal of immunological engineering
    • 1997
    • 318
    • PDF
    Construction, expression, and activity of a bivalent bispecific single-chain antibody.
    • 107
    • PDF
    Assembly of a functional immunoglobulin Fv fragment in Escherichia coli.
    • 933